An open label, phase II trial of afatinib with or without vinorelbine for the treatment of HER2-overexpressing Inflammatory Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2017
At a glance
- Drugs Afatinib (Primary) ; Vinorelbine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 09 Jun 2017 Planned locations also included India as per European Clinical Trials Database
- 01 Dec 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 05 Nov 2014 Planned End Date changed from 1 Oct 2014 to 1 Nov 2014 as per ClinicalTrials.gov record.